3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
6
Terminated
2
Withdrawn
1
Unknown
1
Suspended
1
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Melanoma
6
Leukemia, Myeloid, Acute
3
Carcinoma, Renal Cell
3
Ovarian Cancer Metastatic
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Lymphoma, B-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, B-Cell
1
Kidney Neoplasms
1
Invasive Bladder Cancer Stage IV
1
Hormone Refractory Prostate Cancer
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
Rituximab
15
Cyclophosphamide
12
fludarabine phosphate
11
ibrutinib
10
Bendamustine Hydrochloride
9
fludarabine
7
Peripheral Blood Stem Cell Transplantation
7
Lenalidomide
6
venetoclax
4
Whole-Body Irradiation
4
Radiotherapy
4
idelalisib
3
duvelisib
3
acalabrutinib
3
Mycophenolic Acid
3
Methotrexate
3
Melphalan
3
In Situ Hybridization, Fluorescence
3
Flow Cytometry
3
Filgrastim
3
Cytarabine
3
Cyclosporine
3
ofatumumab
2
obinutuzumab
2
Thiotepa
2
Tacrolimus
2
Pentetic Acid
2
Etoposide
2
Dexamethasone
2
Dasatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Leukemia, Lymphocytic, Chronic, B-Cell
×
Interleukin-2
×
Clear all
NCT00224354
2012-05-21
CLONTAK
Baylor College of Medicine
Phase 1
Withdrawn